| Literature DB >> 31952124 |
Wioleta Cieslik1, Joanna Szczepaniak2, Anna Krasowska2, Robert Musiol1.
Abstract
Styrylquinolines are heterocyclic compounds that are known for their antifungal and antimicrobial activity. Metal complexation through hydroxyl groups has been claimed to be a plausible mechanism of action for these types of compounds. A series of novel structures with protected hydroxyl groups have been designed and synthesized to verify the literature data. Their antifungal activity against wild-type Candida albicans strain and mutants with silenced efflux pumps activity has been determined. Combinations with fluconazole revealed synergistic interactions that were dependent on the substitution pattern. These results open a new route for designing active antifungal agents on a styrylquinoline scaffold.Entities:
Keywords: ABC transporters; Candida albicans; Cdr1p; styrylquinolines
Year: 2020 PMID: 31952124 PMCID: PMC7024281 DOI: 10.3390/molecules25020345
Source DB: PubMed Journal: Molecules ISSN: 1420-3049 Impact factor: 4.411
Figure 1Antifungal quinolines. (1): oxine derivative; (2): 2-phenylquinoline; (3): alkylated oxine; (4): 2-morpholine derivative.
Figure 2The styrylquinolines (SQLs) that were synthesized in this study.
Figure 3Synthesis of the styrylquinolines.
The minimum inhibitory concentration (mg/L) at which 50% of isolates were inhibited (MIC50) for tested styrylquinoline compounds and amphotericin B (AmB) (n = 3).
| Compound | WT (Wild Type Strain) |
|
|
|
|---|---|---|---|---|
|
| >138.8 | >138.8 | >138.8 | 138.8 |
|
| >122.12 | >122.12 | >122.12 | 122.12 |
|
| 26.33 | 3.29 | 26.33 | 3.29 |
|
| >122.12 | >122.12 | >122.12 | 122.12 |
|
| 17.42 | 36.29 | 17.42 | 17.42 |
|
| 19.10 | 39.79 | 19.10 | 19.10 |
|
| 0.9241 | 0.9241 | 0.9241 | 0.9241 |
|
| 18.37 | 0.490 | 0.980 | 0.244 |
The fractional inhibitory concentration (FIC) values for styrylquinoline compounds (n = 3) that were tested.
| Compound | WT (Wild Type Strain) |
|
|
|
|---|---|---|---|---|
|
| 2 | 1 | 2 | 1 |
|
| 2 | 0.5 | 2 | 0.5 |
|
| 0.02 | 0.02 | 0.02 | 0.02 |
|
| 1 | 0.5 | 0.5 | 0.5 |
Figure 4Styrylquinolines (½MIC) influence on energy-dependent rhodamine 6G efflux 30 min after efflux was induced by adding glucose. (±SD, n = 3).
Figure 5Microscopic imagining of the Candida albicans cells. Top panels: differential interference contrast; bottom panels: Cdr1p-GFP. Scale bars = 10 μm.
Figure 6Cdr1p-GFP protein levels in crude protein extracts of the cells after treatment with styrylquinolines (½MIC) as was evidenced by the anti-GFP Western blot (n = 4); DMSO-treated C. albicans cells were used as the control.
Collection of C. albicans strains that was used in this study. Strain CAF 2-1 is treated as a wild-type (WT) strain. The deleted genes encoding drug efflux pumps (Cdr1, Cdr2 and Mdr1) are marked delta in the Genotype column.
| Strain | Genotype | Reference |
|---|---|---|
| CAF 2-1 |
| [ |
| DSY 448 |
| [ |
| DSY 653 |
| [ |
| DSY 654 |
| [ |